Eli Lilly is a global pharmaceutical company founded in 1876. The document analyzes Eli Lilly's competitive position using Porter's Five Forces and SWOT analysis. It identifies key trends in the pharmaceutical industry including mergers and acquisitions, aging populations, expiring patents, and increased regulations. These trends present both opportunities and threats for Eli Lilly. The analysis suggests Eli Lilly should pursue strategies like partnerships, emerging markets, and ongoing R&D to adapt to changes in the competitive landscape over the next 10 years.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
This document provides an overview of the branded generics pharmaceutical market in India and the company Mankind Pharma. It summarizes Mankind's growth and success in the Indian market through organic expansion of its field force and market share, growing its portfolio of branded generic drugs, and expanding globally to over 12 countries. Key metrics shown include its rising domestic market share and rankings over time, high growth rates compared to industry averages, and leadership in key therapeutic segments like anti-diabetics and cardiac drugs.
Brand plan for 2010 glycomet (us vitamin) - mitesh shahMitesh Shah
The document provides a brand plan for Glycomet, a diabetes medication, for the year 2010. It was prepared by Mitesh Shah and submitted to Mr. Pratim Vora. The plan outlines sales objectives to increase annual unit sales and revenue. It discusses strategies and tactics to achieve these objectives, including effective promotional activities, product design, pricing, and a situational analysis. It also includes a SWOT analysis and details on hiring and training sales personnel to support the outlined goals.
Pan (Alkem) Brand Dissertition PresentationDhaval Vaghela
- The document discusses a dissertation on the pantoprazole brand Pan. It provides brand facts, research objectives, findings from research conducted with 150 doctors, a SWOT analysis, and recommendations.
- Key findings include that 36% of doctors named Pan as the first brand that comes to mind for pantoprazole. 44% of doctors said they like nothing about Pan specifically. The most common indications for which doctors prescribe Pan are GERD, hyperacidity, and gastritis.
- Most doctors reported being promoted Pan once or twice per month and prescribing it for 10-20 patients monthly. Overall familiarity with the brand was high but specific attributes liked were low.
Sun Pharmaceuticals is an Indian pharmaceutical company with strong global presence. It has strengths in its expanding emerging markets business, successful acquisition of Ranbaxy, ANDA approvals, and brand presence in India. Opportunities exist in oncology drugs, expanding retail offerings, outsourcing manufacturing, and leveraging Ranbaxy's OTC drugs. However, it faces weaknesses like underperforming subsidiaries, regulatory issues, and pricing controls. Threats include growing generic competition, currency fluctuations, drug pricing policies, and potential financial crunch from acquisitions.
This document outlines the business plan for Losartan Potassium (LOSART) for 2015. It summarizes that hypertension prevalence in Bangladesh is approximately 20% according to different sources. The cardiovascular drug market is valued at 988 crores with antihypertensives comprising 636 crores. LOSART has a 29.24% share of the antihypertensive market as the second most prescribed generic. The plan identifies opportunities to increase market share by focusing on specialty physicians and improving performance in metro areas. Objectives for 2015 include achieving 10% growth, a 4.9% market share, and reaching the number 3 market position.
The document discusses the history and operations of Cipla, an Indian pharmaceutical company. It notes that Cipla was founded in 1935 in Mumbai by Khwaja Abdul Hamied. Currently, Cipla has over 20,000 employees and is a major manufacturer of antiretroviral drugs to treat HIV/AIDS. The document also outlines Cipla's goals, products, locations, patents, financial information, and achievements.
Sun Pharmaceuticals was founded in 1983 and has since grown to be one of the largest pharmaceutical companies globally through strategic mergers and acquisitions. Some of its most significant acquisitions include Ranbaxy Laboratories in 2014, which made it the largest pharmaceutical company in India. Sun Pharma focuses on generic and specialty drugs and generates most of its revenue from sales in the United States. It employs over 32,000 people worldwide and achieved $166 billion in revenue in 2013-2014 through its global manufacturing and distribution network. The company's leadership emphasizes the importance of speed, perfection, and building a strong team to drive continued growth.
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
The brand plan document provides an analysis of an unnamed brand's performance over multiple years. It includes sections on the brand's history, current monthly trends, seasonality, sales analysis, market analysis, regional analysis, corporate scenario, SWOT analysis, and strategy for 2011-2012. Specifically, the document shows that the brand has experienced over 50% growth, commands over 45% of the market share, and has the number one market position. It also provides details on the brand's monthly sales trends, top specialties, regions, and competitors. The document aims to inform the brand's strategic objectives and plans to address issues, communication challenges, and regional strategies and budgets for the upcoming year.
The document discusses launching a new Itraconazole brand called Brintra. It analyzes the large and growing anti-fungal market in India, noting Itraconazole is the top prescribed drug. It examines competitors and finds the top brands have low prices and broad prescriber reach. The SWOT analysis notes strengths in market size and demand, but weaknesses in an overcrowded market. It suggests positioning Brintra through a new formulation technology and price advantage to effectively compete.
This document provides an overview of the pharmaceutical industry in India. It discusses the history and growth of the Indian pharmaceutical market. It also describes the various types of companies, customers, marketing approaches, distribution channels, roles of sales, marketing, and other teams, pricing regulations, and opportunities and changes in the industry. The document is an extensive guide covering many aspects of the pharmaceutical business in India.
This document discusses strategies for launching new pharmaceutical brands. It outlines that successful product launching depends on coordination across functions. The purpose is to build sales. A launching strategy consists of marketing decisions, activities, and product attributes to present the product to its target market. The objectives are to generate income. Key aspects of launching strategy include being first to market, a first follower, or delayed entrant. Marketing decisions include market entry strategy, product positioning, and marketing mix. Strategic decisions involve company strategy, product strategy, market strategy, and competitive strategy. Tactical decisions involve the marketing mix of product, price, promotion, and distribution. Success depends on customer performance, financial performance, and technical performance. The document provides details on various strategic
The document provides an overview of the global and Indian pharmaceutical industries and pharmaceutical marketing. It discusses how pharmaceutical companies research and develop new drugs, the large market size and top companies globally and in India, India's role as a major exporter of generic drugs, and common marketing strategies used in India's prescription-driven branded generic market, which involve establishing relationships with doctors who are the key decision-makers through regular visits and promotion by marketing representatives.
Sun Pharmaceutical Industries was founded in 1983 in Kolkata, India by Dilip Shanghvi. It has since grown to become one of the largest pharmaceutical companies in India through strategic acquisitions and a focus on generic drugs. Some key milestones include acquiring Caraco Pharmaceutical Labs in 1997, acquiring a plant in Ohio in 2005, and merging with Ranbaxy Laboratories in 2014. Sun Pharma has a presence across multiple therapeutic areas and geographic regions. It has a market share of 3.2% in India and follows strict regulatory guidelines. With the aging global population and rising incomes, Sun Pharma is well positioned for continued growth in the coming years through synergies from acquisitions and expanding in emerging markets
Branding and its Potential within the Pharmaceutical Industry
1) Branding is important for pharmaceutical companies to differentiate their products from competitors and build long-term customer loyalty. Strong brands provide value through personalized relationships and competitive advantages.
2) Successful branding requires defining the brand's positioning, personality, values, and unique attributes that support those values. It also involves crafting how the brand visually appears to its audience through elements like name, packaging, and advertising.
3) For pharmaceutical companies, branding is especially crucial due to the highly competitive and regulated nature of the industry. Building brand value and trust takes significant long-term investment but pays off through increased revenue and customer retention.
This presentation provides an overview of Glenmark Pharmaceuticals Limited (GPL), a specialty pharmaceutical company. GPL aims to emerge as a leading global integrated specialty company through proprietary research and development. The presentation outlines GPL's vision, therapeutic focus areas, research pipeline of 13 molecules including 8 new chemical entities and 5 biologics, and progress on key pipeline molecules like Oglemilast and GRC 6211. Financial details and global footprint of the overall Glenmark group are also included.
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.Yee Jie NG
This document discusses scenario planning for Eli Lilly & Co. to explore different possible futures for the pharmaceutical industry over the next 7 years. Four initial scenarios were developed based on two key uncertainties: political landscape in the US and progress of embryonic stem cell research. The scenarios range from a revolutionary transformation of the medical industry with stem cell breakthroughs, to the status quo where no changes occur. Analyzing these scenarios can help Eli Lilly prepare for challenges and opportunities in the uncertain industry environment. Further research is needed to refine understanding of the scenarios and develop quantitative planning methods.
Managers in the pharmaceutical industry face both opportunities and threats due to a dynamic environment. Demand for pharmaceuticals has grown steadily for decades due to demographics and successful new drugs can be highly profitable. However, developing new drugs takes 10-15 years and costs $800 million on average, with many failing. Additionally, incumbent firms face challenges such as upcoming patent expirations, potential price controls, and reduced prices negotiated by large health providers.
The document provides an overview of the global and Indian pharmaceutical industries. It discusses key metrics like global sales, R&D spending, mergers and acquisitions, and future projections. The global pharmaceutical market experienced slow growth in 2012 due to many blockbuster drug patents expiring, but sales are expected to steadily increase to $895 billion by 2018. The Indian pharmaceutical market is also growing, driven by factors like increasing demand from emerging markets, greater acceptance of medical treatment, and a growing elderly population in India.
The document provides an overview of the pharmaceutical industry in India. It discusses that India has emerged as a major player in the global pharma industry, ranking 3rd in volume and 10th in value. The country exports generic drugs and has become an important destination for contract research and manufacturing. The industry is expected to grow significantly, with sales projected to reach $74 billion by 2020. Key strengths that will support this growth include a large talent pool with skills in areas like R&D, manufacturing according to international standards at low costs, and a favorable regulatory environment. However, increased competition and a stringent regulatory environment also pose threats.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies. This represents a long-term strategy change as chronic therapies require doctors to prescribe the same drugs for longer periods. The document also outlines some of the challenges pharmaceutical companies face in marketing to different customers in the supply chain from doctors to patients. It discusses strategies around patents, research and development, and pursuing either a "super core" model focused on a small number of chronic drugs or a "core" model marketing more acute drugs.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies that require long-term treatment. This allows companies to build more stable customer bases. The document also outlines some of the challenges companies face, such as increased competition, high costs of research and development, and complex decision-making processes involving doctors, patients, and other stakeholders. It discusses two common business models - the "super core model" involving a small number of highly successful chronic drugs, and the "core model" involving marketing a larger number of acute drugs.
The document analyzes and dispels five common myths about the drug delivery industry. It argues that far from being a declining sector, drug delivery has delivered steady product approvals over the past decade and continues to be an important source of new products. It also contends that the drug delivery market is growing, drug delivery business models can be sustainable, product line extensions using drug delivery technologies are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions.
This document analyzes and dispels five common myths about the drug delivery industry. It argues that drug delivery has delivered many new products, the market is growing not declining, the business model can be sustainable, product line extensions using drug delivery approaches are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions. The drug delivery industry plays a key role in addressing challenges in pharma by developing improved treatment options.
The document summarizes the changing landscape of the top 10 pharmaceutical companies from 2002 to 2012. It notes that while the companies have remained largely the same, there has been some shuffling between positions. It also discusses how the companies have diversified their business models through mergers and acquisitions, but this has failed to increase their collective market share. The rise of Teva into the top 10 reflects a greater emphasis on generics. Overall, the top companies face challenges in innovating new blockbuster drugs and achieving growth.
This document provides an investor presentation for RedHill Biopharma Ltd. It summarizes the company's drug pipeline including 6 products in various clinical trial phases, with 4 drugs preparing for pivotal phase II/III trials. The company has raised over $12 million and plans to raise approximately $10 million more through an IPO to fund further clinical trials and commercialization efforts. RedHill develops new formulations and uses of existing drugs to treat conditions like Crohn's disease, heart failure, and migraines, pursuing a lower risk business model with significant market potential.
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...Eularis
After years of relatively easy blockbuster profits, worldwide respect and investment, and loyal customer bases, branded pharmaceutical companies are in trouble, increasingly vulnerable to the threats posed by the competition.
And who is that competition? It’s not other branded companies any more. Generics have emerged as the primary challenger to pharmaceutical industry success, offering a public hungry for medications and reduced costs exactly what they want and need. Generics have exploded in the last decades, and are poised for even bigger growth.
The situation is grim. It can seem like pharmaceutical companies have no recourse in the face of the lower prices and operating costs of the generics industry, and fortunes will only continue to fade.
But options do exist for pharmaceutical companies to mount an effective defense strategy against the threats posed by generics.
In this report, we examine some of these defensive strategies. We analyze the environment for pharmaceuticals today, as well as the generic industry as a whole.
We describe the pros and cons of legal defensive strategies, as well as opportunities to expand the revenue-generating product life cycle into reformulations and over-the-counter medications.
We look at pricing strategies, as well as company organizational changes as part of an integrated defense strategy.
And to help companies make tough decisions about the best defense, we examine powerful analytics techniques and case studies.
Mergers and Acquisitions in Pharmaceutical Industry Anjali Makhijani
Mergers and acquisitions have impacted the pharmaceutical industry in several ways. They allow companies to expand their product portfolios and markets through acquiring complementary assets. However, they can also lead to job losses as companies consolidate. Major deals like Pfizer-Wyeth and Ranbaxy-Daichi Sankyo helped the companies strengthen their product pipelines but some deals negatively impacted R&D productivity and employee satisfaction in the long run. Overall, M&As in pharma aim to create shareholder value but often fail to achieve synergies.
The Indian pharmaceutical industry has grown tremendously over the past few decades from being almost non-existent to meeting nearly 95% of the country's pharmaceutical needs. It is now self-reliant in terms of production capabilities across a wide range of medicines. The industry is highly fragmented with over 20,000 registered units and is characterized by intense price competition and government price controls. Exports have also increased significantly and are expected to surpass domestic sales in the coming years, driven primarily by growth in formulation exports. India also has the most FDA-approved manufacturing facilities outside of the US, positioning it as an important supplier for the global pharmaceutical market.
This document provides an overview of research methodology for studying the Indian pharmaceutical market and the effect of healthcare products. The objectives are to understand the market contribution of healthcare products and evaluate consumers' and doctors' attitudes towards these products. Secondary research will gather data from company sources, while primary research will involve interviews with chemists, doctors, and consumers. The study aims to benefit researchers, the sponsoring organization, and colleagues by providing insights into opportunities in the domestic pharmaceutical market.
This document provides an overview of marketing strategies used by pharmaceutical companies in India. It begins with background on the large size of the global pharmaceutical industry and growth of the Indian pharmaceutical industry. The marketing challenges described include increased competition, lack of customer knowledge, and ineffective customer acquisition, development and retention strategies. The document then outlines two common business models - the super core model focusing on a small number of blockbuster drugs, and the core model marketing a larger number of drugs across therapeutic areas. The goals of the proposed research are to identify factors affecting competitiveness, investigate effective customer strategies, and provide alternative strategies to improve competitiveness.
Research Paper Writing
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
Our Mission
“To provide breakthrough research works to our clients through Perseverant efforts towards creativity and innovation”.
Vision
Writekraft endeavours to be the leading global research and publications company that will fulfil all research needs of our clients. We will achieve this vision through:
Analyzing every customer’s aims, objectives and purpose of research
Using advanced and latest tools and technique of research and analysis
Coordinating and including their own ideas and knowledge
Providing the desired inferences and results of the research
In the past decade, we have successfully assisted students from various universities in India and globally. We at Writekraft Research & Publications LLP head office in Kanpur, India are most trusted and professional Research, Writing, Guidance and Publication Service Provider for PhD. Our services meet all your PhD Admissions, Thesis Preparation and Research Paper Publication needs with highest regards for the quality you prefer.
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
Similar to Competitive Analysis in Pharmaceutical Industry (20)
Value Creation Concept and Approach for VCYee Jie NG
1) The document discusses value creation as a service (VCaaS) which involves delivering business and customer development activities to add value to portfolio companies for venture capital firms.
2) It recommends that venture capital firms implement a full value creation program using program management principles to align strategy, people, processes, technology, structure, and metrics. This would provide an end-to-end approach to helping portfolio companies.
3) Steve Blank's customer development model is proposed as a framework for the value creation activities, focusing on discovering customer needs and validating business models and tactics.
The document discusses Kit Ng's background and experience in innovation roles, including developing an IoT prototype to enable active aging and learning that innovations must have clear business models. It also outlines her skills and goals of being goal-oriented, proactive, collaborative, and bringing innovative solutions through understanding customer needs and realities.
A Smart (connected) Hotel is more than implementing WOW factors, it should have the capability to ensure hoteliers to achieve top business goals such as saving operating cost and streamlining operations. Emerging technologies such as IoT and analytics realise the vision of Smart Connected Hotel.
This document discusses various machine learning applications and companies. It provides examples of companies using machine learning for security/fraud detection (BrightPoint Sentinel), HR/recruiting analysis (Textio, hiQ People Analytics), sales recommendations (Sentient Aware), marketing personalization (LiftIgniter), customer support insights (Clarabridge, Quantifind), internal data knowledge management (Alation), and market intelligence (Mattermark). It also discusses machine learning techniques like classification, regression, clustering, and time series analysis. Frameworks mentioned include SAP HANA, SAP Automated Predictive Library, and SAP Lumira.
A new product manager's first 90 days involve: 1) Understanding the product overview and customer value proposition by identifying customer pain points and opportunities through persona and journey mapping; 2) Analyzing the competitive environment to determine product positioning and develop a SWOT analysis; 3) Creating a market penetration strategy including pricing, business model, metrics, and key activities to build a financial model.
Healthcare Landscape and Connected Health Trend of SingaporeYee Jie NG
This deck describes the current healthcare landscape and technology trends in Singapore. It also highlights the global trend and expert's recommendation.
The document explains how digital certificates work and can be validated. It notes that Adobe Reader or Acrobat is required and signatures may not display on tablets or phones. An independent validation process is described where the certificate ID and first name initials can be entered on the issuer's website to validate authenticity. Questions should be directed to the email provided and errors may appear if validation fails or the document has been modified.
IoT@Home aims to demonstrate how wearable and sensor technologies at home can be leveraged to help improve the home living experience, illustrated by better wellness management and enabling active ageing. It also serves to show how these technologies can help promote the development of a broader ecosystem of businesses, by highlighting the rich possibilities enabled by sensor data.
The document discusses Rhythm.SG, a platform that aims to connect various health-related sensor devices to collect data autonomously, comprehend the data into wellness information, and derive knowledge from it. It provides an overview of factors that influence health, strategies for healthy aging, national health statistics in Singapore, potential use cases for technology in health, competitors in the space, and Rhythm's proposed offerings which include APIs and a website to visualize health metrics and synchronize data from wearable devices. The document also outlines plans for the future such as providing diagnoses/prognoses, health tips, and developing mobile apps that integrate with platforms like HealthKit.
The document discusses several events organized by MIC@Cyberjaya to promote technology, innovation and entrepreneurship. It describes an event to set a Malaysia Book of Records for fastest typist. It also discusses workshops and training sessions for students and startups on technologies like Windows Azure and Windows Phone that resulted in prototypes and apps being created. The document also describes a collaboration between MIC@Cyberjaya and Monash University to create an app for a human resources management solution. It further mentions recruiting interns who later formed startups and teams for competitions.
Strategic Marketing: A Case Study of StarbucksYee Jie NG
The document discusses Starbucks' global expansion and marketing strategies. It covers Starbucks' product levels including their core, actual and augmented products. It also discusses their product classification, individual product decisions around attributes, branding, packaging and services. It analyzes how Starbucks builds brand equity, customer equity and positions its brand. Finally, it discusses Starbucks' approach to international marketing issues and recommendations for continuous global expansion.
Project Management: New Product Development for Amazon Ceramic IndustriesYee Jie NG
This document summarizes a new product development project for 25x40cm wall tiles by Amazon Ceramics Industries. The project aims to launch 4 new tile series at the upcoming MALBEX 2010 exhibition to increase profits. A budget of RM493k is allocated for equipment, marketing materials, and event expenses. Key deliverables include producing tile samples, mock installations, brochures, SIRIM certification, and an exhibition booth. The project objectives, timeline, risks, and assumptions are also outlined.
The document discusses marketing strategies for Cialis, a drug manufactured by Eli Lilly for treating erectile dysfunction. It analyzes Cialis' current market performance and competitors. Recommendations are provided to help Cialis improve its marketing mix and target new customer segments to become market leader. Suggestions include enhancing brand positioning, developing new packaging, improving the website, increasing public education on erectile dysfunction, and leveraging a hybrid online/offline distribution channel. The goal is for Cialis to maximize its strengths and provide more value to customers through an effective marketing plan aligned with Eli Lilly's objectives.
Change Agent Strategies: Emotion of ChangeYee Jie NG
This document discusses managing emotions during organizational change. It begins by stating that change is personal and involves feelings, yet emotions are often ignored in management. It then discusses how emotions color perception and are critical to change projects. It describes different emotional states people experience during change, such as denial, resistance, and commitment. The document presents models for understanding how emotions affect behavior and outlines strategies managers can use to help people transition through change, such as communication, training, and facilitating exploration of new roles. These strategies aim to minimize discomfort during the change process.
2. Preface
Competitive Analysis of Eli Lilly to
determine its market position in
pharmaceutical industry by identifying
issues & challenges using SWOT analysis &
Porter’s Five Forces in determinant of
industry attractiveness for Eli Lilly
The future directions & strategies will be
of assistance for Eli Lilly to meet the
urgent & crucial challenges.
2
3. Content
1. Introduction
• 1.1 Team Members
• 1.2 The Company – Eli Lilly & Co.
2. Porter’s Five Forces (Current
Situation)
3. The Key Trends in
Pharmaceutical Industry
• 3.1 Mergers & Acquisitions (M&A)
• 3.2 Outsourcing
• 3.3 Cost Control
• 3.4 Expiring Patents
• 3.5 Aging Populations
• 3.6 Food & Drugs Authority (FDA) Regulations
• 3.7 Emerging Disease
4. S.W.O.T. Analysis
5. Eli Lilly Driving Forces
• 5.1 Merger and Acquisition (M&A) Emergence of New
Biotech Companies
• 5.2 Aging Population and New Emerging Market
• 5.3 Expiration of Patents and Emergence of Generics
6. Porter’s Five Forces (New Situation)
• 6.1 Rivalry Among Competing Firms in Industry
• 6.2 Bargaining Power of Buyers
• 6.3 Threat of Substitute Products
• 6.4 Threat of New Entrants
• 6.5 Bargaining Power of Suppliers
7. The Future Direction & Strategies of
Eli Lilly
• 7.1 Mergers & Acquisitions (M&A)
• 7.2 Outsourcing
• 7.3 On-going R&D for New Drugs – Emergence Market for
Aging Population and New Geographic Market Penetration
• 7.4 Regulatory & Government Affair Capabilities & Patents
8. Conclusion
3
5. Team Members
Chee Liung Wun
2821927
Lim Shieh Chern
2821959
Ng Yee Jie
2821942
Terrenz Leong
2821913
Winny Low
2821920
5
6. The Company - Eli Lilly & Co.AboutUs
Global,
research-based
pharmaceutical
company and
one of the
world's largest
corporations.
Origin
Founded in
1876 by a
retired colonel
& Pharmacist,
Eli Lilly. Global
headquarter in
Indianapolis,
United States
Mission
To makes
medicines that
help people live
longer,
healthier, more
active lives
6
7. Eli Lilly & Co.
• Today, marketed in 143 countries, 10th largest pharmaceutical
company in world. Steadfastly remained independent, but not isolated.
Global headquarters in Indianapolis, United States
• Global employees’ number approximately 40,000, and its medicines
are marketed in 143 countries.
• Major research and development facilities in 8 countries and conducts
clinical trials in more than 50 countries.
7
9. Porter’s Five Forces (Current
Situation)
Porter’s Five Forces: Determinant
of Industry Profitability (Current)
9
10. Porter’s Five Forces (Current
Situation)
Threat of Substitute
Products
LOW
(Low Value, Risk)
Threat of New
Entrants
LOW
(Patent, regulatory
process & Dist
System)
Rivalry Among Competing
Firms in Industry
LOW
(Different niches & Patent
Protection)
Bargaining Power of
Buyers
LOW
(Insurance companies,
doctors‘& patients’
buying habit)
Bargaining Power
of Suppliers
LOW
(Multiple sources)
10
11. Our Main Focus
To evaluate the key trends in pharmaceutical
industry.
To identify how these trends apply to Eli Lilly
currently.
To discover the influences of competitive
dynamics within the industry for the next 10
years. 11
12. The Key Trends in
Pharmaceutical Industry
Mergers &
Acquisitions
(M&A)
Outsourcing Cost Control
Expiring
Patents
Aging
Populations
Food &
Drugs
Authority
(FDA)
Regulations
Emerging
Disease
12
13. Mergers & Acquisitions (M&A)
To improve sales & increase competiveness in the
healthcare industry
To better position themselves to remain competitive
To create mutual benefit through sharing resources &
complement each other on their product pipelines
To increase their shopping lists & product pipelines
with a handful of highly prospective blockbuster drugs
13
14. Mergers & Acquisitions (M&A)
No Name of Company Merger/Acquisition Year
1 Bayer and Schering AG Acquisition 2006
2 Merck KG aA and Serono Acquisition 2006/2007
3 Nycomed and Altana Pharma Acquisition 2006/2007
4 UCB and Schwarz Pharma Acquisition 2007
5 Mitsubishi and Tanabe Merger 2007
6 Schering-Plough and Organon Acquisition 2007/2008
7 AstraZeneca and Medlmmune Acquisition 2007
8 Mylan and Merck Serono Acquisition 2007
9 Eisai and MGI Pharma Acquisition 2007/2008
10 Takeda and Millennium Acquisition 2008
11 Eli Lilly and ImClone Acquisition 2008
12 Daiichi-Sankyo and Ranbaxy Acquisition 2008
13 Pfizer and Wyeth Acquisition 2008
14 Merck and Schering-Plough
(currently on negotiation)
Merger 2009
List of M&A
undertaken
between
2006 - 2009
Source : Report: Mergers and Acquisitions in the Pharmaceuticals Sector, 2009
14
15. Outsourcing
• Dramatic & durable
changes to the
operating
environment.
• The eroding pricing
power, patent expiring
& tighter regulatory
standards.
Reasons
• Companies to
outsource their non-
core business, such as
preclinical activities to
third party
Resulted • The core business,
cost control & speedy
delivery
To Focus
15
16. Cost Control
• New generic are
competing for
expiring patents.
• The global financial
crisis
Reasons
• Many companies
has undertaken
cost cutting
exercise as one of
the measure
Resulted • To lowing fixed cost
& eliminating
redundancy
To Focus
16
17. Cost Control
Top Five Layoff in
Pharmaceutical Industry
(2007)
Total
Layoff
Top Five Layoff in
Pharmaceutical Industry
(2008)
Total
Layoff
Pfizer 10,000 Merck 8,400
AstraZeneca 7,600 Schering-Plough 5,000
Bayer 6,100 Wyeth 5,000
Johnson & Johnson 5,000 UCB Pharma 2,000
GlaxoSmithKine 5,000 AstraZeneca 1,400
Data show the total no. of layoff in 2007 &
2008 in the pharmaceutical industry 17
18. Expiring Patents
“Many branded-name drugs lose patent protection will
leading to a WAVE of generic medications entering the
market”
(Quoted from Article “Flooded Generic Pipeline Looms as Branded Patents Expire”)
About 183 of branded drugs will go
off patent starting 2009 until 2013
$60 billion worth of drugs are going
off by 2011
18
19. Brand Name Drug Patent
Expirations
51%
17%
22%
3%
7%
Brand Name Drug Patent Expirations
2006 2007 2008 Ex-2009 2009
Source: Expiring Patents Ignite Biotech Boom & Flooded Generic Pipeline Looms as Branded Patents Expire
19
20. Aging Populations
Fact
• An increasing aging
population is another
trend that affects the
pharmaceutical
industry
Current
• 6 countries account for
54% of the total
number aged 80 years
or over
• China (12mil), U.S.A.
(9mil), India (6mil),
Japan (5mil), Germany
(3mil) & Russian
Federation (3mil)
Future
• In 2050, 6 countries
will have more than 10
million people aged 80
years or over
20
21. Aging Populations
The average expenditure for prescription drugs
for people age 65 & above increased 130%,
rising from $819 in 1997 to $1,914 in 2004.
Source: Drug Spending Increases More Than 2.5 Times in 8 Years 21
22. Food & Drugs Authority (FDA)
Regulations
• Glaxo Smith Kline (GSK)
Fail to inform physicians that
studies had shown that its highly
profitable drug Paxil, despite
ineffective in adolescents, it also
contribute to some cases of suicide
Becoming stricter in
approving new drugs
after a series of
lawsuits & scandals
involving prestigious
pharmaceutical firms
• ImClone
Erbitux drug failed to get approval
from FDA in late 2001, causing the
company’s stock price to plummet
severely
It is very common to
see the stock of these
companies skyrocket
(or plummet) as test
data is released
22
23. Emerging Disease
Emerging diseases
like SARS, Bird Flu,
Aids & the recent
type A Influenza
H1N1
Roche who own the
proprietary drug, Tamiflu
that can treat bird flu &
type A influenza H1N1 took
full advantage of the
situation
Threaten human kind in the form of a
global pandemic
Share price of Roche skyrocketed & attracted
popular & media attention to the industry 23
25. Strengths
Research-based pharmaceutical
company & is one of the largest
corporation
Existing patent protection for a number
of years on key products
Marketing strength in major
geographical & therapeutic areas
25
26. Weaknesses
Patent expiring for few patent
blockbuster drugs such as Zyprexa,
Cymbalta & Evista in year 2010 & 2014
Discontinuation of products in the latter
stages of development
26
27. Opportunities
Emergence of global markets (China,
Vietnam, etc) & aging population
Decreasing development time through
favorable R&D collaborations & internal
efforts
27
28. Threats
Expiring of patent protection for a
number of years on key products
Increase in growing of generic market
Government policy to support generic
products
28
29. Eli Lilly Driving Forces
Merger and
Acquisition (M&A)
Emergence of New
Biotech Companies
Aging Population
and New Emerging
Market
Expiration of
Patents and
Emergence of
Generics
29
30. M&A Emergence of New Biotech
Companies
Current trend of M&A has
changed the pharmaceutical
landscape dramatically
With emergence of many
Behemoth pharmaceutical firms
like Pfizer & Merck which has
become stronger in term of
product development, market
penetration, etc
Many new biotech companies
that have developed some highly
potential innovated & niche
products. This has hastened the
need to speed up the
development of products in the
pipeline
The stricter regulation of FDA
that tend to slow down the
development of drugs in the
pipeline also has resulted the
Company to embark on the
similar exercise in order to
remain competitive in the market
30
31. Aging Population and New
Emerging Market
The large pool of “growing” market that focus on diagnosis
& treatment of illness for old age people, ie, diabetics,
Alzheimer or cardiovascular drugs.
Zydus Cadila, an India based drug maker on the R&D
conducted the joint research program, which could
continue for up to 6 years for developing drugs for
cardiovascular diseases
As part of the agreement, Lilly will have the option to
license the result at different stage
If Lilly is able to successfully develop the product, it will
help the Company to increase their product pipeline &
through patent the drug, the Company will able to secure
the sale volume at least for another 15-20 years
Source: www.ibtimes.co.in/articles/20090401/cadila-healthcare-inks-research-development
31
32. Expiration of Patents and
Emergence of Generics
• The oncoming patent expirations & generic pressure
• Sales of the 3 blockbuster drugs were raked in 2006 for
a combined $6.8bil, nearly half of the Company’s total
revenue
• The fierce emergence of generics which increase pricing
pressures and spiraling drug development costs
New Challenges
• Between 2011 & 2014, Lilly will lose patents on 3 big
name drugs: Zyprexa, Cymbalta and Evista
Patents Lost
Source: Eli Lilly signals vigour for outsourcing 32
33. Porter’s Five Forces (New
Situation)
Rivalry
Among
Competing
Firms in
Industry
Bargaining
Power of
Buyers
Threat of
Substitute
Products
Threat of
New
Entrants
Bargaining
Power of
Suppliers
33
34. Porter’s Five Forces (New
Situation)
Threat of Substitute
Products
MODERATE
(OTC alternative)
Threat of New
Entrants
MODERATE
(Increased Biotech
Firms)
Rivalry Among Competing
Firms in Industry
MODERATE
(Generics more common,
price pressure)
Bargaining Power of
Buyers
MODERATE
(Buyer Consolidate, Large
governmnet players &
hospitals price sensitive)
Bargaining Power
of Suppliers
MODERATE
(Multiple sources)
34
35. Rivalry Among Competing Firms
in Industry
• To explore a broader differentiation
strategy & attract wide range of customer
• Increase premium price, increase unit
sales & gain buyer brand loyalty
Explore
• Increase R&D activities
• Incorporate features that raise product
performance
• To avoid replacing old products
R&D
35
36. Rivalry Among Competing Firms
in Industry
● Competes against the Pfizer’s Viagra in
the erectile dysfunction market.
● CIALIS’ has 36 hours potency as
compared to Viagra’s 4 hours.
● Lesser side effects & lasts longer in the
body to increase spontaneity.
● The longer duration of effect is ideal for
partners who seek for freedom & flexibility
to choose the right moment for sexual
activity.
CIALIS
Source: The Edge, 2005 36
37. Bargaining Power of Buyers
Doctors’ bill are increasing & outpacing the general inflation rate each year
worldwide.
The global medical inflation average 10% each year.
Generic drugs can help patient save between 60% to 90% on their medical bills
according to a recent study by the school of Pharmaceutical Sciences at USM,
Malaysia)
Government & private hospitals are now relying more on generic drugs to
mitigate the effects of rising medical costs
Patient looks for cheaper alternative like generic drugs to ease their burden, e.g.,
India is famous for its generic drugs & biosimilars.
Patent law since 1970s had allowed scientists could take a brand name drug &
reverse-engineer it to create similar drug with the same effects.
37
38. Threat of Substitute Products
Self-care lifestyle
• Demands of expensive
patented drugs are
expected to decline
Modernizing traditional
Chinese Medicine (TCM)
• China recently announced
a US$10 billion “Mega
New Drug Development
Programme”, with the aim
of growing its drug
development industry over
the next 13 years, which
accounts for 38% of
medical products
produced in China in 2007
• Cheaper cost
38
39. Threat of Substitute Products
Burrill stated 3 forces that will shape the
healthcare industry:
Molecular &
personalized
medicine
Wider access
to lower
costs and
high quality
healthcare
Proficient use
of health
information
39
40. Threat of Substitute Products
Molecular & personalized medicine
• Genetic screening can identify people risk profile for lethal diseases
• Advances in molecular biology and genomics have shown that the efficacy of
personalized medicine can be improved by taking a holistic view of the person
• Knowing well ahead the conditions and heritage of body will translate to
prevention and lower healthcare bills
Wider access to lower costs and high quality healthcare
• In next few years, the patents of blockbuster drugs from major pharmaceuticals
will expire
• This could signal a boom in generic drugs in the market, which means that drugs
will get cheaper and be available to more people
Proficient use of health information
• Monitoring devices can be implanted or worn and data can be transferred to
secure systems, which allow doctors to effectively monitor and advice patients
• Preventive measures are better than wait until someone is sick and then only
start treating them 40
41. Threat of New Entrants
The threat of new entry
by biotech companies is
increasing.
Highly potential
innovative products being
developed by the very
agile & innovative
biotech companies.
It may only take a super
blockbuster drug for
these small biotech firms
to change the entire
pharmaceutical industry
landscape.
Fortunately due to their
small size, very few
biotech firms have
managed to develop
their own marketing &
distribution channels.
41
42. Bargaining Power of Suppliers
Suppliers have strong bargaining power because
they can ensure quality materials supplies under
the purview of regulated body
Active Phamaceutical
Ingredient Committee
(APIC), who is a section
of The European
Chemical Industry
Council (Cefic) guards
the European
pharmaceutical
producers to ensure
they do not purchase
counterfeit or rogue
ingredients
Penalty is extremely
heavy of any offender.
Without a patent
protection, ethical
pharmaceutical
companies will not be
able to compete with
generic producers from
China or India who have
less stringent law on
source of raw materials
Therefore, Lilly has
established a strong
business relationship
with a few suppliers so
that it will not succumb
to bargaining power of
suppliers
Source: Oldenhof, 2008
42
43. The Future Direction &
Strategies of Eli Lilly
Mergers &
Acquisitions (M&A)
Outsourcing
On-going R&D for
New Drugs –
Emergence Market
for Aging Population
& New Geographic
Market Penetration
Regulatory &
Government Affair
Capabilities &
Patents
43
44. Mergers & Acquisitions (M&A)
Future Directions
• Joint venture
• Acquired small
biotechnology
companies which have
products that
complement with
Lilly’s product
Recent
Pharmaprojects
• November 2008, Lilly
acquired ImClone
System (lacks
marketing &
distribution channels)
as wholly-owned
subsidiary
• ImClone brought four
preclinical, two Phase
I, two Phase II, one
Phase III & one
launched anticancer
MSb to the table
Source : Company Analysis – M&A in 2009 44
45. Mergers & Acquisitions (M&A)
Future Directions
• Tapping on the skills
& knowledge within
2 firms.
• M&A helps to
eliminate
competitors.
• Acquiring a biotech
firm that owns a
proprietary drug
that competes in the
same market
segment.
Recent
Pharmaprojects
• Lilly acquired PCS
Health Systems for
$4 billion.
• A prescription
benefits-
management
company (PBM)
which provides
prescription drugs to
health maintenance
organizations & the
employees of large
corporations.
Source: Nichols, 1994
45
46. Outsourcing
Company involved outsourcing exercise
basically due to reasons as follows:
Outsiders can perform certain activities better or cheaper
Allows a firm to focus its energies on those activities at
the centre of its expertise or core competencies that are
the most critical to its competitive and financial success
Source: Thompson, Strickland III & Gamble, 2005, p. 175
46
47. Outsourcing
• To fill up its dwindling new product pipeline
to accelerate recovery from many
impending patent expirations
• To provides competitive services &
innovative capabilities from the talent
pool
• To fully utilize overseas market like,
whose R&D costs continue to escalate
• To diversify operation strategies to
handle FDA who required clinical trials to
target much larger populations instead of
sub-populations resulted slowdown in the
new products launches
• To operate in a leaner shape, forming
itself into a “network structure” that made up
of 3rd party service providers & contract firms
Benefits
• To outsource non-core
activities, such as
cleaners, some of the
manufacturing section,
sales representatives
& IT works
Future
Directions
47
48. Outsourcing
• China & India has a strong base
of CROs (contract research
organizations) & CMO
(contract manufacturing
organizations) to support the
changing business models of
western companies
• The jobs are human clinical
trial testing, side effect
testing, product life cycle
testing & chemical trial
testing
Benefits
• Outsourced the
non-competitive or
non competencies
job functions to
India & China
Recent Action
48
49. On-going R&D for New Drugs
Future
Direction
• The emergence aging population market
Strategies
• To focus on R&D for aging diseases drugs, such as
cardiovascular drugs
• To acquire smaller pharmaceutical companies with the
expertise to develop drugs for diabetics &
Alzheimer to shorten the drug launch time
Source : Company Analysis – M&A in 2009
49
50. On-going R&D for New Drugs
Future
Direction
• China, Vietnam market could emerging middle class
income groups
Strategies
• To explore overseas market to increase its earning
through increase in sales.
• To facilitate the access to penetrate the local market besides
taking advantages of their skill, knowledge & expertise.
• Recent Lilly’s project: developing drugs for cardiovascular
diseases.
Source : Company Analysis – M&A in 2009
50
51. Regulatory & Government Affair
Capabilities & Patents
Strategies
Lilly has developed its regulatory & government affair capabilities
by external recruitment of regulatory & government affair
personals to work with & lobby government agencies like FDA &
Health departments on drug regulatory related issues
Future Directions
To protect patent & prevent multibillion lawsuits on ethical issues
51
52. Regulatory & Government Affair
Capabilities & Patents
Strategies
Lilly has placed an Adverse Drug Experience reporting monitoring
system, which facilitates further remedial actions like product recalls.
New policies on ethical interaction & promotion of pharmaceutical
products for all its employees
Future Directions
To establish itself as an ethical pharmaceutical firm
52
53. Regulatory & Government Affair
Capabilities & Patents
Strategies
Lily could undertake to ease the impact of patent expiration are listed in next
slide…
Future Directions
To increase in distribution channels
To achieve economic of scale & allow Lilly to sell drugs at cheaper rate to the
developing countries such as India & 3rd world countries
53
54. Regulatory & Government Affair
Capabilities & Patents
Maximize promotional activities
to strengthen.
Acquisition or partnership with
the generic firms in order to bring
out their own generic version of
the drug
Heavy discount to products
soon patent expiring drugs to gain
patient & physician loyalty.
Re-engineer the products. One
way of doing it is to amend the
different dosage strength.
Switch products from prescription to over-the-counter (OTC) status.
For example, SmithKline-Beecham create a milder version of Tagamet
that does not require prescription to counter the emergence of generic
drug.
Source : Agrawal et. al., 1997
Special Strategies…
54
55. Conclusion
• Besides, smaller biotech firms that
are increasingly agile & innovative
must also be guarded, as it may
only take a super blockbuster drug
for these small biotech firms to
change the entire pharmaceutical
industry
• Although there are still many
untapped potential,
pharmaceuticals cannot
expect profits like the golden
era of pharmaceutical industry
in the 1990s, but be prepared
for a moderate to serious
decline in profits
• Established & global
expertise of firms including
Lilly & its rivals like Pfizer,
GSK and Merck which
manufacture proprietary
drugs have a much better
chance to reap emerging
global opportunities as
compared to firms producing
generics
• Pharmaceutical Industry
although will experience
more competition &
challenges which will affect
its profitability, its still a
profitable industry to
venture in relative to many
other industries
Profitable
Industry
Good
Opportunities
Beware of
smaller
biotech firms
Moderate to
Decline
Profits
Many new biotech companies that have developed some highly potential innovated & niche products.
This has added on to the already very fierce competition in the pharmaceutical industry
Hastened the need to speed up the development of products in the pipeline.
Statistic shows after 10 or 12 years in general, patents expire & lower-priced generics come in, wiping out the revenues of blockbuster drugs in a matter of weeks.
PBMs provide drugs to large corporations at lower costs because of their high volume of sales & their power to negotiate low prices with pharmaceutical companies.